IVIG preparations show significant intratypic variation in enterovirus antibody titres, suggesting batch selection for specific treatment should be based on the patient's own isolate rather than reference strains.
Answers are grounded in this paper and cite their sources.
IVIG titre variability may limit efficacy against enterovirus strains; leaves open whether isolate-specific batch selection improves outcomes in trials.
Antibody titres in immunoglobulin preparations for intravenous use were tested against 24 different enterovirus serotypes and varied between 1:100 and 1:10,000 within a single batch. Differences up to 8-fold were found for homologous titres between two different batches that were prepared 6 years apart. The lowest titre obtained was 1:40. The observed differences within and between the two batches could not be explained by different incidence of serotypes of enteroviruses circulating at the time blood was collected. Differences in titres of up to 18-fold were observed when several strains of the same serotype were tested suggesting that intratypic variation influences antibody titres. It is concluded that immunoglobulin preparations contain antibodies against many enteroviruses, but that titres can be low and cannot be predicted from the incidence of any particular serotype circulating in the community. Because of intratypic variation, selection of a batch for specific treatment should be based on results obtained with the patient's own isolate, and not with a reference strain.
No takes yet. Share an insight, caveat, or question.
Galama et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: